Role of toll-like receptor 4 on the immune escape of human oral squamous cell carcinoma and resistance of cisplatin-induced apoptosis

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Sun, Zujun ^a   Luo, Qingqiong ^a   Ye, Dongxia ^b   Chen, Wantao ^b   Chen, Fuxiang ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Lipopolysaccharide; Myeloid differentiation primary response gene 88; Oral squamous cell carcinoma; Toll like receptors

Indexed keywords

CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUTH MUCOSA; MOUTH SQUAMOUS CELL CARCINOMA; PROTEIN EXPRESSION;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; MOUTH NEOPLASMS; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TUMOR ESCAPE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860821450     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-33     Document Type: Article

References (34)

1. Kademani D. Oral cancer. Mayo Clin Proc 2007, 82:878-887. 10.4065/82.7.878, 17605971.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
3. Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z, et al. Toll-like receptors in tumor immunotherapy. Clin Cancer Res 2007, 13:5280-5289. 10.1158/1078-0432.CCR-07-1378, 2131730, 17875756.
4. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801. 10.1016/j.cell.2006.02.015, 16497588.
5. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 2007, 13:460-469. 10.1016/j.molmed.2007.09.002, 18029230.
6. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511. 10.1038/nri1391, 15229469.
7. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003, 21:335-376. 10.1146/annurev.immunol.21.120601.141126, 12524386.
8. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, Xiong H. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005, 65:5009-5014. 10.1158/0008-5472.CAN-05-0784, 15958541.
9. He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007, 44:2850-2859. 10.1016/j.molimm.2007.01.022, 17328955.
10. Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, Szyfter W, Zeromski J, Whiteside TL. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009, 69:3105-3113.
11. Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E, Spaczynski M, Whiteside TL. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 2009, 28:4353-4363. 10.1038/onc.2009.289, 2794996, 19826413.
12. O'Neill LA. When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. Immunity 2008, 29:12-20. 10.1016/j.immuni.2008.06.004, 18631453.
13. Macagno A, Molteni M, Rinaldi A, Bertoni F, Lanzavecchia A, Rossetti C, Sallusto F. A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression. J Exp Med 2006, 203:1481-1492. 10.1084/jem.20060136, 2118317, 16717116.
14. Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N, et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000, 10:33-41.
15. Hefler LA, Grimm C, Ackermann S, Malur S, Radjabi-Rahat AR, Leodolter S, Beckmann MW, Zeillinger R, Koelbl H, Tempfer CB. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res 2003, 63:3066-3068.
16. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003, 3:1-19.
17. Duan Z, Feller AJ, Toh HC, Makastorsis T, Seiden MV. TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 1999, 229:75-81. 10.1016/S0378-1119(99)00042-6, 10095106.
18. Clinchy B, Fransson A, Druvefors B, Hellsten A, Hakansson A, Gustafsson B, Sjodahl R, Hakansson L. Preoperative interleukin-6 production by mononuclear blood cells predicts survival after radical surgery for colorectal carcinoma. Cancer 2007, 109:1742-1749. 10.1002/cncr.22623, 17345614.
19. Vaquero J, Campbell JS, Haque J, McMahon RS, Riehle KJ, Bauer RL, Fausto N. Toll-like receptor 4 and myeloid differentiation factor 88 provide mechanistic insights into the cause and effects of interleukin-6 activation in mouse liver regeneration. Hepatology 2011, 54:597-608.
20. Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T. Azzam Eel D, Khalifa A: Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004, 37:363-369. 10.1016/j.clinbiochem.2004.01.014, 15087251.
21. Lokshin AE, Winans M, Landsittel D, Marrangoni AM, Velikokhatnaya L, Modugno F, Nolen BM, Gorelik E. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol 2006, 102:244-251. 10.1016/j.ygyno.2005.12.011, 16434085.
22. McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV, Connolly DT, Robertson DM. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994, 344:235-236. 10.1016/S0140-6736(94)93001-5, 7913160.
23. Campoli M, Ferrone S, Zea AH, Rodriguez PC, Ochoa AC. Mechanisms of tumor evasion. Cancer Treat Res 2005, 123:61-88. 10.1007/0-387-27545-2_3, 16211866.
24. Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C, Bouchier-Hayes D, Dong Z. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 2002, 101:415-422. 10.1002/ijc.10632, 12216068.
25. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998, 92:4150-4166.
26. Park HJ, Park OJ, Shin J. Receptor activator of NF-kappaB ligand enhances the activity of macrophages as antigen presenting cells. Exp Mol Med 2005, 37:524-532.
27. Chen R, Alvero AB, Silasi DA, Mor G. Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol 2007, 57:93-107. 10.1111/j.1600-0897.2006.00441.x, 17217363.
28. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP, Bours V. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003, 22:90-97. 10.1038/sj.onc.1206056, 12527911.
29. Kojima M, Morisaki T, Izuhara K, Uchiyama A, Matsunari Y, Katano M, Tanaka M. Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-kappa B activation. Oncogene 2000, 19:1225-1231. 10.1038/sj.onc.1203427, 10713711.
30. Nakashima H, Nakamura M, Yamaguchi H, Yamanaka N, Akiyoshi T, Koga K, Yamaguchi K, Tsuneyoshi M, Tanaka M, Katano M. Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. Cancer Res 2006, 66:7041-7049. 10.1158/0008-5472.CAN-05-4588, 16849549.
31. Hsu RY, Chan CH, Spicer JD, Rousseau MC, Giannias B, Rousseau S, Ferri LE. LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. Cancer Res 2011, 71:1989-1998. 10.1158/0008-5472.CAN-10-2833, 21363926.
32. Qian Y, Deng J, Xie H, Geng L, Zhou L, Wang Y, Yin S, Feng X, Zheng S. Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling. J Cancer Res Clin Oncol 2009, 135:379-386. 10.1007/s00432-008-0478-z, 18825409.
33. Zhong LP, Yang X, Zhang L, Wei KJ, Pan HY, Zhou XJ, Li J, Chen WT, Zhang ZY. Overexpression of insulin-like growth factor binding protein 3 in oral squamous cell carcinoma. Oncol Rep 2008, 20:1441-1447.
34. Zhong LP, Pan HY, Zhou XJ, Ye DX, Zhang L, Yang X, Chen WT, Zhang ZY. Characteristics of a cancerous cell line, HIOEC-B(a)P-96, induced by benzo(a)pyrene from human immortalized oral epithelial cell line. Arch Oral Biol 2008, 53:443-452. 10.1016/j.archoralbio.2007.12.002, 18206853.